Nutrition 21 will continue to vigorously defend its intellectual property portfolio. These ongoing business initiatives will strengthen the significant competitive advantages enjoyed by our customers, continued Ms. Montgomery. Jon de la Harpe, Ph.D., AMBI s Senior Vice President and Chief Science Officer noted, Nutrition 21 s patent portfolio supports an essential mineral ingredient whose broad reaching health benefits are just beginning to be appreciated. We have expanded our clinical research program to better understand the cascade of metabolic reactions associated with chromium picolinate, and its effects on glycemic control and insulin regulation. Forward-looking statements are based on the company's current expectations and are subject to market, competitive and regulatory factors and the other risks and uncertainties indicated from time to time in the company's filings with the Securities and Exchange Commission.
Actual results can differ materially.
The company makes no commitment to disclose any revisions to forward-looking statements.